SCRIB and neoplasm: Interestingly, MET treatment increased the expression of SCRIB in the two drug‐resistant cells (LCC2 and MCF/TAX) and in mouse tumours, but only had a weak effect in drug‐sensitive cells (MCF7; Figure 6B,C).